Plain language review: the safety of relugolix combination therapy for advanced prostate cancer.

IF 3 4区 医学 Q2 ONCOLOGY Future oncology Pub Date : 2024-11-06 DOI:10.1080/14796694.2024.2409543
Jose De La Cerda, Jared Thorley, Paul Sieber, Michael S Cookson, Scott C Flanders, Sergio C Gatoulis, Neal D Shore
{"title":"Plain language review: the safety of relugolix combination therapy for advanced prostate cancer.","authors":"Jose De La Cerda, Jared Thorley, Paul Sieber, Michael S Cookson, Scott C Flanders, Sergio C Gatoulis, Neal D Shore","doi":"10.1080/14796694.2024.2409543","DOIUrl":null,"url":null,"abstract":"<p><strong>What is this summary about?: </strong>Advanced prostate cancer is a cancer that began in the prostate (a part of the male body) and has spread to other parts of the body. This is a review of two clinical research studies of patients with advanced prostate cancer who were treated with relugolix combination therapy. Relugolix is a medicine taken by mouth that lowers a male sex <b>hormone</b>, called testosterone. Relugolix is sometimes combined with other medicines such as novel hormonal therapies (NHTs) or chemotherapy to treat advanced prostate cancer. In one study, patients were treated with relugolix combined with an NHT (abiraterone or apalutamide). In a second study, patients were treated with relugolix combined with an NHT (enzalutamide) or chemotherapy (docetaxel). Researchers wanted to understand what possible <b>side effects</b> may happen due to taking these medicines together as prescribed. They also wanted to see if relugolix combination therapy worked to lower testosterone in the same way as relugolix taken alone.</p><p><strong>What are the key takeaways?: </strong>Researchers found that most of the side effects of relugolix combined with an NHT or chemotherapy were mild or moderate. Side effects of relugolix combination therapy were similar to the side effects of the medicines when taken alone. However, patients who received relugolix with enzalutamide or docetaxel were more likely to have a serious side effect compared with patients who received relugolix taken alone. Testosterone stayed below 50 nanograms per deciliter (known as castration levels) for patients who received relugolix with NHT or chemotherapy.</p><p><strong>What were the main conclusions reported by the researchers?: </strong>Patients who receive relugolix combination therapy generally experience mild or moderate side effects, rather than serious side effects. No new safety issues were found during these studies. Patients maintained low testosterone levels. Patients and their doctors should discuss the benefits and possible harms of relugolix combination therapy to treat advanced prostate cancer.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2409543","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

What is this summary about?: Advanced prostate cancer is a cancer that began in the prostate (a part of the male body) and has spread to other parts of the body. This is a review of two clinical research studies of patients with advanced prostate cancer who were treated with relugolix combination therapy. Relugolix is a medicine taken by mouth that lowers a male sex hormone, called testosterone. Relugolix is sometimes combined with other medicines such as novel hormonal therapies (NHTs) or chemotherapy to treat advanced prostate cancer. In one study, patients were treated with relugolix combined with an NHT (abiraterone or apalutamide). In a second study, patients were treated with relugolix combined with an NHT (enzalutamide) or chemotherapy (docetaxel). Researchers wanted to understand what possible side effects may happen due to taking these medicines together as prescribed. They also wanted to see if relugolix combination therapy worked to lower testosterone in the same way as relugolix taken alone.

What are the key takeaways?: Researchers found that most of the side effects of relugolix combined with an NHT or chemotherapy were mild or moderate. Side effects of relugolix combination therapy were similar to the side effects of the medicines when taken alone. However, patients who received relugolix with enzalutamide or docetaxel were more likely to have a serious side effect compared with patients who received relugolix taken alone. Testosterone stayed below 50 nanograms per deciliter (known as castration levels) for patients who received relugolix with NHT or chemotherapy.

What were the main conclusions reported by the researchers?: Patients who receive relugolix combination therapy generally experience mild or moderate side effects, rather than serious side effects. No new safety issues were found during these studies. Patients maintained low testosterone levels. Patients and their doctors should discuss the benefits and possible harms of relugolix combination therapy to treat advanced prostate cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通俗易懂的评论:瑞舒利联合疗法治疗晚期前列腺癌的安全性。
摘要:晚期前列腺癌是一种始于前列腺(男性身体的一部分)并已扩散至身体其他部位的癌症。这是一篇关于两项临床研究的综述,研究对象是接受瑞乐戈利联合疗法治疗的晚期前列腺癌患者。瑞乐戈利是一种口服药物,可降低一种名为睾酮的雄性激素。瑞乐戈利有时会与新型荷尔蒙疗法(NHTs)或化疗等其他药物联合使用,以治疗晚期前列腺癌。在一项研究中,患者接受了瑞乐戈利与一种NHT(阿比特龙或阿帕鲁胺)的联合治疗。在第二项研究中,患者接受了瑞格列奈与NHT(恩扎鲁胺)或化疗(多西他赛)联合治疗。研究人员希望了解按照处方同时服用这些药物可能会产生哪些副作用。他们还想看看relugolix联合疗法降低睾酮的效果是否与单独服用relugolix的效果相同:研究人员发现,瑞格列奈与非甾体抗炎药或化疗联合使用的副作用大多为轻度或中度。瑞格列奈联合疗法的副作用与单独用药时的副作用相似。不过,与单独服用relugolix的患者相比,接受relugolix与恩杂鲁胺或多西他赛联合治疗的患者更有可能出现严重的副作用。研究人员报告的主要结论是什么?接受瑞格列奈联合疗法的患者一般会出现轻度或中度副作用,而不会出现严重副作用。在这些研究中没有发现新的安全性问题。患者的睾酮水平仍然较低。患者和他们的医生应该讨论瑞格列奈联合疗法治疗晚期前列腺癌的益处和可能的危害。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Future oncology
Future oncology ONCOLOGY-
CiteScore
5.40
自引率
3.00%
发文量
335
审稿时长
4-8 weeks
期刊介绍: Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
期刊最新文献
Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. Part 1 - Highlights of the San Antonio Breast Cancer Symposium 2023. Part 2 - Highlights of the San Antonio Breast Cancer Symposium 2023. Targeting CDK2 to combat drug resistance in cancer therapy. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1